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ABSTRACT
The long-term goals and objectives of our group are to identify bioactive
natural products relevant to human disease prevention and health promotion.
To attain this goal, the objective of this thesis was to demonstrate that
bioactive polyphenol-rich extracts exert positive health benefits beyond basic
nutrition, thus impacting overall health and wellness. We believe that this
project has immense scientific merit from a human health perspective and will
be of great public impact given that consumers are seeking natural and
organic choices for improving health. In this investigation, we have focused
our attention on investigating the biological activities of two novel phenolic-rich
preparations derived from curcumin and maple syrup for future nutraceutical
applications.
The work herein assessed the anti-inflammatory properties of novel
standardized curcumin formulation (Longvida®) and phenolic-enriched maple
syrup

extract

using

a

well-known

in

vitro

model

of

inflammation,

lipopolysaccharide (LPS)-induced RAW 264.7 murine macrophages. RAW
264.7 cells were co-treated with 50 ng/mL LPS and test extracts for 24 hours
and then inflammatory markers were measured using gene and protein
expression. The activation of nuclear factor-kappa B (NFκB) was measured
using luciferase activity. Both polyphenolic extracts were able to inhibit the
LPS stimulated inflammation by down-regulating the inflammatory markers via
targeting nuclear factor-kappa B (NFκB) (a major pathway modulated in
inflammation) transcriptional activity in murine macrophages.

Next, the work herein studied the anti-hyperglycemic and anti-lipogenic
properties of novel standardized nutraceutical grade phenolic rich extract,
(MSX). Human HepG2 hepatoma cells were treated with MSX for 24 h.
Glucose consumption, AMP activated protein kinase (AMPK) activation and its
target gluconeogenic gene expression were measured. The glucose levels
were reduced by MSX in the hepatocytes though AMPK activation.
Subsequently, the anti-lipogenic effect of MSX treatment in mature
differentiated 3T3-L1 murine adipocytes and human visceral adipocytes was
evaluated. MSX treatment to mature adipocytes decreased lipid accumulation,
compared to control, in both murine and human adipocytes.

In 3T3-L1

adipocytes, this effect was associated with downregulation of adipo/lipogenic
protein expression (e.g. PPARγ, Srebp1c). We also observed reduced mRNA
expression of the pro-inflammatory mediators, namely IL-6, and TNF-α.
Taken together, we demonstrated that a novel maple syrup extract exhibited
anti-inflammatory, anti-hyperglycemic and anti-lipogenic activities in vitro.
The current study adds to the growing body of in vitro and in vivo data
supporting the biological effects and potential health benefits of the novel
curcumin formulation Longvida® and the natural sweetener, maple syrup.
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PREFACE

The following dissertation titled “Evaluation of in vitro anti-inflammatory, antidiabetic and anti-lipogenic activity of natural polyphenolic extracts and their
pure constituents” is presented in manuscript format. There are three
manuscripts in this dissertation. First chapter is introductory and serves as a
general background for manuscript one, two and three. Manuscript one is
formatted in Journal of Medicinal Food (J Med Food) journal style, second
manuscript is in Journal of Functional Foods (J Funct Foods) style, and the
third is in The Journal of the Federation of American Societies for
Experimental Biology (FASEB J.) format. Manuscripts one and two are
published in peer-reviewed journals as of March 2015.
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Introduction

The rapid growth of health foods, also known as nutraceuticals, has
immensely impacted consumers. Though variety of oral drug formulations is
available, there is an increasing trend towards using nutraceuticals for
prevention of diseases or as adjuncts to conventional therapies (1). Botanical
extracts, produced from medicinal plants and plant foods, are widely
consumed worldwide as dietary supplements for the promotion and
maintenance of human health. Herbal natural products constitute a major
approach of Complementary and Alternative Medicine (CAM) that is widely
utilized by consumers. Recently, market statistics show the growing attention
and confidence that consumers place in the herbal dietary supplements. In
2013 alone, herbal dietary supplements sales were increased by 7.9%, and
reported a sales figure of six billion dollars for the herb market. The 20 topselling herbal supplements in the natural and health foods channel in the
United States includes turmeric, flax seed/oil, wheat or barley grass and
cranberry etc. (2). These natural products are typically ‘whole extracts’
constituting complex mixtures of multiple substances found within the plant
rather than a single compound alone.

This has arisen out of a basic

underpinning of the biological effects of botanical extracts, namely, ‘the sum of
the whole is greater than its parts’ due to synergy, additivity and/or
complementary effects among multiple constituents.
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A growing body of research suggests that plant natural products, both in
purified or extract forms, have anti-inflammatory properties and may impart
beneficial effects against diseases with an inflammatory component (3-6).
Dietary intake of bioactive class of compounds ‘phenolics’ with antioxidant and
anti-inflammatory

properties

represents

one

mechanism

to

combat

inflammation and promote overall human health. Polyphenols play a
significant role in human nutrition and health, as these potent bioactive
constituents are the most abundant phytochemicals in our diet (7-10). Possible
efficacy of phenolics including biological extracts such as grape seed extracts,
cocoa extracts, etc or pure constituents like resveratrol, curcumin. on
inflammation, glucose and lipid homeostasis has been well published in cell
culture studies, animal models and some clinical trials (14,11-13)
It is now well accepted that inflammation and associated pro-inflammatory
processes are centrally linked to several chronic human diseases including
cancer, diabetes, cardiovascular and neurodegenerative diseases (15-17).
Regulatory mechanisms that monitor metabolism and immunity overlap with
each other at many stages (18). The factors contributing to metabolic diseases
like diabetes and obesity are insulin resistance, impaired glucose and lipid
metabolism (19). As stated earlier, along with chronic inflammation, altered
balance of pro-inflammatory and inflammatory factors are also involved in the
pathogenesis of these metabolic diseases. Multiple complex molecular
pathways that involve JNK, NFκB, SOCS, AMPK and PPAR family members
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are responsible for development of hepatic insulin resistance by inflammation
(18).
The Nuclear factor kappa B (NFκB) signaling pathway has been well
characterized and is considered to be a predominant signaling pathway in
inflammation (15, 16). The activated form of NFκB has been reported to be
involved in chronic inflammatory diseases such as cancer, atherosclerosis,
myocardial infarction, diabetes, arthritis, Alzheimer’s disease, osteoporosis,
and other (20-22). Thus, agents that can suppress NFκB activation, such as
plant natural products can potentially prevent, delay the onset, or treat NFκB linked diseases (23-25). Moreover, many well-known antioxidants that are
currently being marketed in nutraceutical preparations, such as resveratrol,
curcumin, and pomegranate, are thought to elicit anti-inflammatory effects
through downregulation of the NFκB signaling pathway in macrophages (26,
27). Hence, in manuscript two and three we have demonstrated the antiinflammatory activities of standardized curcumin formulation Longvida® and
polyphenolic maple syrup extract in RAW 264.7 macrophage model.
In the first manuscript, ‘Anti-inflammatory effects of novel standardized
solid lipid curcumin formulations’, we have investigated in vitro biological
effects of Longvida®, a commercially available standardized novel curcumin
formulation, on the NFκB signaling pathway which is a major molecular
pathway involved in inflammation (15, 16). The investigations carried out in
last few decades, confirmed that curcumin (the most active constituent of the
curry spice turmeric) targets many transcription factors (NFκB, ATF3, AP-1,
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STAT-3), inflammatory mediators (NO, PGE2, cytokines), enzymes, growth
factors, protein kinases and cell-cycle regulatory proteins (27-30). Despite the
promising health benefits of curcumin, water insolubility, low bioavailability and
poor absorption are the limiting factors for the use of curcumin as a potential
preventive and therapeutic agent (29, 31). Lately, very promising results were
observed in an in vivo single-dose pharmacokinetic study of standardized
novel solid lipid curcumin particle (SLCP) preparation (Longvida®), which
reported 65 fold increased bioavailability of the preparation relative to generic
curcumin extract and suggests the potential for sustained release dosage form
(32). Furthermore an acute and subchronic toxicity study in rats and mice
demonstrated the safety of SLCP and the No Observed-Adverse-Effect Level
(NOAEL) was determined to be 720 mg/kg bw/day, the highest dose tested
(33). Moreover, a recent study demonstrated that a low dose of a Longvida®
(80 mg/ day) can produce a variety of potentially health promoting effects in
healthy middle-aged people (34). Yet the effects of this bioavailable curcumin
preparation Longvida® on inflammation remains unknown and detail
investigation is needed. Thus, in the first manuscript we focused our attention
on evaluating anti-inflammatory effects of this novel nutraceutical formulation
Longvida®.
In the second manuscript, ‘Phenolic mediated anti-inflammatory properties
of a maple syrup extract in Raw 264.7 murine macrophages’, we
demonstrated that maple syrup extract attenuated lipopolysaccharide induced
inflammation via NFκB pathway in the same murine macrophage model that
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was used in manuscript 1. Herein we have also investigated anti-inflammatory
activities of fifteen pure compounds isolated from maple syrup extract. Maple
syrup is a widely consumed natural sweetener with well-studied chemistry.
Canada and eastern North America are chiefly responsible for the major
commercial production of available maple syrup. Being the world’s largest
maple syrup supplier, this industry plays a critical role in the economy of this
region. Maple syrup is a very interesting food to investigate, primarily due to its
unique chemical profile. This natural sweetener constitutes mainly of
carbohydrates (sucrose) along with various nutrients such as minerals,
vitamins, amino acids, organic acids, phytohormones (abscisic acid, phaseic
acid and their metabolites) and most importantly various phytochemicals
(majorly phenolics belonging to the sub-classes lignan, phenolic acid, stilbene,
coumarin, and flavonoid). The chemistry of maple syrup has been extensively
studied; however there are very few biological studies that have been
conducted. Thus, in this study we investigated the mechanistic insights into
the anti-inflammatory activity of maple syrup extract and it’s pure constituents.
We believe that accomplishing this project has lead to increased scientific
knowledge on the ‘matrix’ effects of multiple constituents exerting positive
biological effects to this sweetener beyond sucrose alone. This project is thus
necessary along the research continuum on this natural product.
Our maple syrup research has lead to the development of the first
nutraceutical grade botanical extract from this food (named MSX) (35). Initially,
the laboratory scale maple syrup extract project was focused on inflammatory
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pathways but gradually it evolved, and then we started exploring the
mechanisms involved in metabolic diseases like diabetes, obesity etc. that has
chronic inflammatory component using food grade extract MSX. In the third
manuscript titled, ‘In vitro hypoglycemic and lipid lowering effects of a
standardized food grade maple syrup extract (MSX)’, we have explored
glucose lowering and lipid lowering potential of a nutraceutical grade MSX
extract using hepatocytes and adipocytes respectively.
Searching for a signaling mechanism for the hypoglycemic action of MSX
extract, we have explored its effect on 5' adenosine monophosphate-activated
protein kinase (AMPK) activation in human HepG2 hepatoma cell model.
AMPK, a heterotrimeric serine/threonine kinase, is a vital metabolic regulator
of fatty acid and glucose homeostasis. It is emerging as a potential target for
the treatment of diabetes and chronic inflammatory diseases (19). Numerous
studies have reported that the activation of AMPK can inhibit NFκB signaling
indirectly, a master regulator of inflammation, both in vitro and in vivo (36).
Recently, activation of AMPK by metformin, a first-line anti-diabetic drug, has
been shown to decrease glucose production and increase fatty acid oxidation
in the liver (37, 38). It has been reported that AMPK activation by polyphenols
may be at least partially responsible for their therapeutic benefits on
hyperlipidemia in diabetes (39).
Moreover, there is a strong interplay between inflammation, diabetes and
obesity. Adipocyte dysfunction has been linked to the development of type 2
diabetes, insulin resistance along with sub-clinical inflammation. Polyphenolic
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compounds such as catechins, resveratrol etc. have modulatory effects on
many complex pathways in adipose tissue including upregulation of fatty acid
oxidation and reduction in the expression of the transcription factors, enzymes
and genes involved in lipogenesis e.g. peroxisome proliferator-activated
receptor γ (PPARγ), CCAAT enhancer-binding protein-α (C/EBP-α), Sterolregulatory element-binding protein 1-c (Srebp-1c), fatty acid binding protein
(FABP4), fatty acid synthase (FAS), and perillipin, etc. (14). A natural
polyphenol, resveratrol has been shown to attenuate adipogenesis and
lipogenesis in both murine and human adipocytes including mature and
differentiating adipocytes cell models. Resveratrol has been used in several
clinical trials and exhibited its effectiveness in inflammatory conditions and
metabolic diseases. Thus, in this third manuscript, we investigated MSX
effects on lipogenic pathways and adipo/lipogenic transcription factors in
mature murine and human adipocytes. This study has provided data that will
support the design of future preclinical trials with maple bioactives.
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1.1. Abstract
Inflammation and the presence of pro-inflammatory cytokines are associated
with

numerous

chronic

diseases

such

as

type-2

diabetes

mellitus,

cardiovascular disease, Alzheimer's disease, and cancer. An overwhelming
amount of data indicates that curcumin, a polyphenol obtained from the Indian
spice turmeric, Curcuma longa, is a potential chemopreventive agent for
treating certain cancers and other chronic inflammatory diseases. However,
the low bioavailability of curcumin, partly due to its low solubility and stability in
the digestive tract, limits its therapeutic applications. Recent studies have
demonstrated increased bioavailability and health promoting effects of a novel
solid lipid particle formulation of curcumin (Curcumin SLCP, Longvida®). The
goal of the current study was to evaluate the aqueous solubility and in vitro
anti-inflammatory effects of SLCP formulations using lipopolysaccharide
(LPS)-stimulated RAW 264.7 cultured murine macrophages. SLCPs treatment
significantly decreased nitric oxide (NO) and prostaglandin-E2 (PGE2) levels at
concentrations ranging from 10-50 µg/mL, and reduced Interleukin-6 (IL-6)
levels

in

a

concentration-dependent

manner.

Transient

transfection

experiments using a nuclear factor-kappa B (NF-κB) reporter construct
indicates that SLCPs significantly inhibit the transcriptional activity of NF-κB in
macrophages. Taken together, these results show that in RAW 264.7 murine
macrophages, SLCPs have improved solubility over unformulated curcumin,
and significantly decrease the LPS-induced pro-inflammatory mediators NO,
PGE2 and IL-6 by inhibiting the activation of NF-κB.
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1.2. Introduction
Inflammation and associated pro-inflammatory processes are centrally linked
to several chronic human diseases including cancer, diabetes, obesity,
arthritis,

cardiovascular

and

neurodegenerative

diseases1-6.

During

inflammation, macrophages play a critical role in managing various
immunopathological phenomena, including the overproduction of inflammatory
markers such as nitric oxide (NO), prostaglandin-E2 (PGE2), tumor necrotic
factor α (TNFα) and cytokines like interleukin-6 (IL-6) and interleukin-1β (IL1β). A number of inflammatory stimuli, for e.g. lipopolysaccharides (LPS) and
pro-inflammatory cytokines, activate immune cells to produce inflammatory
mediators, and these are therefore useful targets in the development of novel
anti-inflammatory drugs and in the evaluation of the molecular mechanisms of
potential anti-inflammatory drugs7, 8. Thus, dietary agents that can suppress
inflammatory markers, such as plant natural products, can potentially prevent,
delay the onset, and/or treat inflammation and inflammatory-mediated
diseases. A growing body of research suggests that plant phenolic compounds
which possess antioxidant and anti-inflammatory properties offer an attractive
dietary strategy to combat inflammation and promote human health and
wellness 9, 10.
Curcumin (diferuloylmethane) is derived from the ground rhizomes of
the Curcuma longa L. plant and is the most active curcuminoid in the Indian
curry spice, turmeric11,

12

. Curcumin is a lipophilic, water insoluble, low

molecular weight polyphenol (MW = 368 g/moL), which has been used for
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culinary applications in many parts of the world. In Ayurveda, turmeric is
widely used to treat a variety of conditions ranging from acute infections,
wounds, and injuries in addition to chronic diseases like diabetes, asthma, and
various inflammatory diseases13-15. A vast number of published research
studies support a wide range of pharmacological effects of curcumin including
anti-oxidant, anti-cancer, anti-Alzheimer’s disease and anti-inflammatory
effects both in vitro and in vivo

13, 16

. On a molecular level, curcumin targets

many transcription factors (including NF-κB, AP-1, STAT-3), inflammatory
mediators (PGE2, cytokines), enzymes, growth factors, protein kinases and
cell-cycle regulatory proteins 13, 17-19
Despite the promising health benefits of curcumin, its low water solubility
limits its oral delivery in aqueous-based formulations which are popular among
consumers and widely used in the nutraceutical and functional food industries.
Moreover, the

poor bioavailability and extensive phase-II metabolism of

curcumin are limiting factors for the oral dosage of unformulated curcumin
which limits its potential as a preventive and/or therapeutic agent19, 20. Various
Clinical

trials have reported low systemic bioavailability of curcumin even after

oral administration of doses up to 12 g/kg/day

16, 21

. Several research

strategies have been undertaken to improve the bioavailability of curcumin,
including blocking non-specific metabolic pathways, as well as novel drug
delivery systems and formulations like liposomes, nanoparticles and
phospholipid complexes

13, 22

. In a clinical study, a combination of curcumin

and piperine, a nonspecific CYP-450 and (UDP-glucuronosyltransferase) UGT
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inhibitor, resulted in increased curcumin bioavailability, but with an absorption
half-life of only 7 minutes

23

. Other in vitro studies suggest that polymer-based

nanoparticle formulations of curcumin, also known as ‘nano-curcumin’, exhibit
pharmacological activity at slightly lower concentrations than that of pure
curcumin in human pancreatic cancer cell lines

24

. However, the potential

increase in bioavailability of these latter formulations is offset by the lack of
data and clinical trials on the safety and metabolism of nanoparticle
formulations in humans.
Recently, a single-dose human pharmacokinetic study of a standardized
novel solid lipid curcumin particle (SLCP) preparation (commercially available
as Longvida®) reported increased bioavailability compared to a generic
curcumin extract, suggesting the potential for sustained release dosage forms
of this natural product25. Moreover, acute and sub-chronic animal toxicity
studies by Dadhaniya et al. (2011) demonstrated the safety of the SLCP and
the No Observed-Adverse-Effect Level (NOAEL) was determined to be 720
mg/kg bw/day which was the highest test dose26. In addition, DiSilvestro et al.
(2012) demonstrated that a low dose of a Longvida® (80 mg/day) imparted
potentially health promoting effects in healthy middle-aged humans27. Also, in
a recent investigation, Longvida® selectively suppressed soluble Tau dimers
and corrected molecular chaperone, synaptic, and behavioral deficits in
transgenic mice suggesting that this curcumin formulation may have potential
beneficial effects against Alzheimer’s disease28. However, to date, the effects
of this bioavailable curcumin preparation, namely, Longvida®, on inflammation
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and inflammatory biomarkers remains unknown.
The goal of the present study was to evaluate the effects of two novel
SLCP preparations using LPS-stimulated RAW 264.7 macrophages, a wellestablished in vitro anti-inflammatory model. LPS increases inflammatory
markers such as NO, PGE2 and IL-6 and we hypothesized that the
standardized SLCP formulations would block the expression of proinflammatory mediators.

1.3. Materials and Methods
1.3.1. Solid Lipid Curcumin Particle (SLCP) Formulations and Curcumin
Extract
The solid lipid curcumin particle (SLCP) preparation (Longvida®, SLCP-1), a
solution-dispersible SLCP preparation (Longvida® SD, SLCP-2), and a
curcumin extract (containing 95 % curcuminoids) were provided to our
laboratory by Verdure Sciences (Noblesville, IN, USA). The SLCP extracts
were produced using patent-pending methodology as described previously25,
27

and were standardized to contain approximately 20 % curcumin25, 26. SLCP-

1 is a granular powder used for tablets and capsules, and SLCP-2 is a fine
powder intended for use in other dosage forms. Briefly, turmeric root extract
was mixed with pure phosphatidylcholine, vegetable stearic acid, ascorbic acid
(vitamin C) palmitate, and other inert ingredients. The formulations were
manufactured under cGMP standards and meet internal and external
specifications for precise chemical and physical characteristics. The solubility
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of the two SLCP formulations and the curcumin extract are shown in Table 1
(data provided by Verdure Sciences).

1.3.2. Cell culture
RAW 264.7 mouse macrophage cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA). RAW 264.7 cells were routinely
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10
% v/v fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100
µg/mL) (Sigma-Aldrich, St. Louis, MO) and maintained at 37 ºC with 5 % CO2
humidified air. Stimulated RAW 264.7 cells (1 x 105/100 µL) were treated with
50 ng/mL LPS (Sigma-Aldrich, St. Louis, MO) with or without different
concentrations of test samples (10, 25, and 50 µg/mL) for 24 h.

All test

samples were solubilized in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St.
Louis, MO) with a final DMSO concentration < 0.1% in the culture medium.
Cell culture supernatants were collected for nitrite (NO), PGE2, and cytokine
assays.

1.3.3. Cytotoxicity Assay
The viability of RAW 264.7 macrophages after 24 h of continuous exposure to
the test compounds was determined by performing colorimetric MTS [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymeth-oxyphenyl)-2-(4-sulphenyl)-2Htetrazolium salt] assay (Promega, Madison, CA) according to the protocol
described previously but with minor modifications29. Briefly, after 24 h of
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treatment, 20 µL of MTS reagent was added to each reaction well (in a 96-well
format). After 2 h of incubation, the absorbance was measured at 490 nm
using a spectrophotometer (SpectraMax M2, Molecular Devices Corp,
Sunnyvale, CA).

1.3.4. Nitrite determination
RAW 264.7 macrophages were plated in a 96-well plate (1 × 105 cells/100 µL)
and incubated at 37 °C for 24 h. After 24 h, the medium was replaced and the
cells were co-treated with 50 ng/mL LPS and different concentrations of the
SLCP formulations (10, 25 and 50 µg/mL) for 24 h at 37 °C. Cells that were
not treated with LPS served as a negative control. After 24 h, the cell culture
supernatants were collected and incubated (1:1, v/v) with modified Griess
reagent

(1%

sulfanilamide

in

5%

phosphoric

acid

and

0.1%

naphthylethylenediamine dihydrochloride in distilled water) (Sigma-Aldrich, St.
Louis, MO) for 20 min at room temperature as previously described30. The
absorbance at 540 nm was measured using a spectrophotometer (SpectraMax
M2, Molecular Devices Corp, Sunnyvale, CA). The nitrite concentration was
quantified by comparison with a sodium nitrite standard curve. The assay was
performed in triplicate for each concentration.

1.3.5. PGE2 determination
To evaluate the effects of various concentrations of the SLCP-1 and SLCP-2
formulations on PGE2 levels, PGE2 metabolites accumulated in the cell
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supernatants were measured using a PGE2 enzyme-immunoassay (EIA) kit
(Cayman Chemical, Ann Arbor, MI), according to the manufacturer’s protocol.
The assay was performed in triplicate for each concentration.

1.3.6. Determination of IL-6
The effects of the SLCP-1 and SLCP-2 formulations on the production of proinflammatory

cytokine

IL-6

was

determined

by

Bio-Plex®

Multiplex

Immunoassays (BioRad Laboratories, Hercules, CA), as described by the
manufacturer’s instructions. The experiment was performed in quadruplicate.

1.3.7. Transient transfection and luciferase assay
LPS-induced NF-κB upregulation accounts for a part of LPS-mediated
activation of variety of inflammatory genes and hence it is important to identify
the effects of SLCP formulations on the transcriptional activity of NF-κB

31

. To

monitor these effects of the two SLCP formulations, RAW 264.7 macrophages
were transiently co-transfected with pNF-κB and pRL-CMV reporter vectors
(Promega, Madison, CA) using GenePORTER® 3000 Transfection Reagent
(Genlantis, San Diego, CA) according to the manufacturer’s protocol. Briefly,
the cells were seeded into 96-well plates (1.2 × 104 cells/100 µL) in complete
medium without antibiotics (DMEM +10 % FBS) and incubated for 24 h (~5070 % confluency). Cells were then treated with the transfection complexes and
incubated for 72 h before treatment with each SLCP formulations (10, 25, and
50 µg/mL) for 2 h. LPS was added after 2 h (1 µg/mL). After 5 h, cells were
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lysed with 20 µL passive lysis buffer and NF-κB activity was measured as
relative firefly/renilla luciferase activity using a Dual-Luciferase® Reporter
Assay System (Promega, Madison, CA) with a GloMaxTM 20/20 Luminometer
(Promega, Madison, CA) according to the manufacturer’s protocol. All samples
were tested in quadruplicate. Luciferase activity was recorded as relative light
units (RLU) and expressed as fold change relative to LPS-treatment control
and the assay was performed using three replicates for each concentration.

1.3.8. Statistical analysis
All statistical analyses were carried out using the software program GraphPad
Prism Version 5.0 (GraphPad Software, La Jolla, CA). Experimental data were
grouped by one variable and were analyzed by one-way ANOVA followed by a
Dunnett's multiple comparison test. A value of p < 0.05 was considered
significant.

1.4. Results
1.4.1. Aqueous solubility of SLCP formulations vs. curcumin
The SLCP-1 and SLCP-2 formulations were both soluble in water, with SLCP1 possessing ca. 14 % solubility and SLCP-2 having ca. 76 % solubility (see
Table 1). On the other hand, the curcumin extract exhibited significantly less
solubility in water which was in agreement with the previous data published by
Kurien et al. (2007)32. Given this solubility data as well as the previously
published data supporting the increased bioavailability of the SLCPs
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compared to a generic curcumin extract in humans, 25 we proceeded to further
evaluate the SLCP formulations in targeted in vitro bioassays (described
below).

1.4.2. Effect of SLCP formulations on LPS-induced NO production
NO and PGE2 are secreted into cell culture supernatant by RAW 264.7 murine
macrophages when they are treated with LPS. Since NO is highly unstable,
the accumulation of nitrite (a stable oxidized product of NO) in culture media is
often used as a biomarker for NO production in LPS-activated macrophages33.
A nitric oxide assay was used to evaluate the effect of the SLCP formulations
on NO production as described in section 2.4. RAW 264.7 cells were
incubated with or without LPS (50 ng/mL) in the presence or absence of test
samples (10, 25 and 50 µg/mL) for 24 h. In LPS-stimulated macrophages,
nitrite levels increased significantly to 88.7 ± 6.2 µM as compared to the
solvent control (Fig. 1A). In Fig. 1A, treatment with SLCP formulations
suppressed nitrite concentration in LPS-activated macrophages in a
concentration-dependent manner. At 25 µg/mL, both SLCP formulations
significantly decreased medium nitrite to 33.5 ± 4.2 µM and 61.6 ± 2.0 µM
respectively. At 50 µg/mL, SLCP-1 and SLCP-2 both inhibited LPS-induced
NO production in macrophages by 100 %. No nitrite production could be
detected in cells treated with test compounds without LPS (data not shown).
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1.4.3. Effect of SLCP on PGE2 production
We next evaluated the effects of SLCP on LPS-induced PGE2 synthesis in
RAW 264.7 cells. The same supernatants were used for measurement of
PGE2. After stimulation with LPS (50 ng/mL), PGE2 was released into the
culture medium and rapidly converted into its metabolite. As shown in Fig. 1B,
at 10 µg/mL SLCP-1and SLCP-2 lowered LPS-induced PGE2 production to
about 31 and 25 %, respectively. Treatment with 25 µg/mL of SLCP-1 and
SLCP-2 significantly suppressed PGE2 levels by about 66 and 64 %
respectively, whereas both the test compounds at 50 µg/mL concentration
reduced PGE2 levels to about 96 % as compared to control. The SLCP
formulations did not significantly increase PGE2 levels in cells which were not
treated with LPS (data not shown). Thus our results show that SLCPs inhibited
PGE2 production in a concentration-dependent manner in LPS-stimulated
cells. The test compounds were not responsible for altering the viability of
activated macrophages as determined by MTS assay (see Supplementary
Fig.1). Hence, the observed reduction in NO and PGE2 production by the
SLCP treatments was not attributed to cytotoxic effects.

1.4.4. Effects of SLCPs on the levels of IL-6
LPS induction in macrophages causes the up-regulation of pro-inflammatory
cytokines such as IL-6 34. Consequently, the effect of varying concentrations of
the test compounds on this cytokine was evaluated. LPS treatment
significantly elevated levels of IL-6 (6043 ± 589.94) in the media (Fig. 2). IL-6
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levels in macrophages treated with the test compounds alone, without LPS,
were negligible (data not shown). The SLCP formulations suppressed IL-6
levels in a concentration-dependent manner. At 25 and 50 µg/mL of SLCP-1
treatment, IL-6 levels were significantly reduced by 29.4 and 97.4 %
respectively. Similarly, treatment with 10, 25 and 50 µg/mL of SLCP-2
decreased IL-6 production by about 2, 13 and 95 %, respectively. This data
suggested that, both SLCP formulations were effective in lowering IL-6 levels
in LPS-stimulated macrophages, with SLCP-1 being slightly more effective
than SLCP-2 at higher concentrations.

1.4.5. Effects of SLCP formulations on NF-κB activation
The activation of the transcription factor, NF-κB is a key-step in stimulating
pro-inflammatory signals. Thus, we next investigated the effect of the SLCP
formulations on NF-κB activity, by transient transfection of macrophages
followed by luciferase assay. After treatment with 1 µg/mL LPS, the NF-κB
activity of the macrophages was significantly increased as compared to control
(Fig. 3). Treatment with the SLCPs formulations significantly reduced NF-κB
transcription activity in a concentration dependent manner, as shown in Fig. 3.
NF-κB luciferase activity was decreased to almost 10-fold with 10 µg/mL of
SLCP-1 treatment, whereas with 10 µg/mL of SLCP-2, the activity was
reduced to about 6-fold as compared to control.
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1.5. Discussion
Inflammation is a key component in multiple disease states35. Based on a
review of the literature, the NF-κB signaling pathway is the predominant
upstream molecular signaling pathway that causes inflammation through
enhanced cytokine, nitric oxide, and prostaglandin production36. Several
studies in different animal models and in human trials support the diverse
pharmacological
angiogenic,

effects

anti-oxidant,

of

curcumin

including

anti-inflammatory,

anti-proliferative,

anti-microbial,

hepato-

antiand

nephro-protective properties etc.22. The SLCPs are novel proprietary curcumin
formulations with improved solubility and bioavailability compared to generic
curcumin.
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In this study, we investigated the inhibitory effects of the SLCP

treatments on the inflammatory response initiated by LPS in RAW 264.7
macrophages.
In inflammation, macrophages undergo sequential steps to release proinflammatory mediators like cytokines, NO and PGE2. These molecules recruit
other immune cells to the sites of inflammation. Therefore inhibition of the
release of these chemicals is a good strategy for monitoring inflammatory
diseases 35.
In the current study, we reported that LPS-activated RAW 264.7 murine
cells treated with improved-solubility curcumin formulations, namely, SLCP-1
and SLCP-2, exhibited concentration-dependent down regulation of NO and
PGE2 production. These observations were in agreement with the previous
studies, which reported the inhibition of NO through the suppression of
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inducible, NO synthase gene and protein expression by curcumin in LPS and
IFN-γ activated RAW 264.7 macrophages37, 38. Our study further revealed that
the SLCP treatments on LPS-activated macrophages decreased IL-6 levels in
a concentration dependent manner. It has been demonstrated previously that
there is a reduction in LPS-induced IL-6 levels with curcumin treatment in
macrophages

39, 40

. Moreover, it was reported that curcumin blocked the LPS-

induced NF-κB activation through the prevention of Inhibitor κB degradation in
RAW 264.7 cells 38. Thus, the down regulation of NF-κB activation can be one
of the many mechanisms underlying the anti-inflammatory effects of the
SLCPs.
The improved solubility of SLCP formulations compared to regular
curcumin (see Table 1) may be due to the amphiphilic nature of SLP
formulations that utilize phospholipids and other lipids to solubilize curcumin in
aqueous solutions. In previous studies, similar types of formulations
contributed to the creation of micelle type physical structures that permit
increased dissolution of lipophilic compounds. SLCP-1 and SLCP-2 differ with
respect to powder size, and the differential solubility between them (Table 1)
may be due to the relative amount of surface area exposed to the aqueous
medium. In this study, it was found that SLCP-2 possessed greater water
solubility than SLCP-1, likely due to its decreased powder size and thus
increased surface area exposed to the aqueous solution. However, both
SLCPs possessed similar activity in vitro on inflammatory mediators. Future
research may investigate the dissolution and micellar characteristics of these
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formulations and their interactions with cytokines on a molecular level. Overall,
the increased aqueous solubility of the SLCP formulations compared to natural
curcumin leads to a broader scope of possible formulations which can be
utilized by the nutraceutical and functional food industries.
In toto, solid lipid curcumin particle (SLCP) formulations dosedependently

mitigated

the

LPS-induced

inflammatory

response

in

macrophages, by down regulation of the production of the inflammatory
markers NO, PGE2 and IL-6 through inhibition of NF-κB activation. SLCP-1
was slightly more effective at inhibiting the anti-inflammatory response than
SLCP-2, and this may be due to concentration-dependent effects. The current
findings suggest the use of increased-water soluble curcumin formulations
such as SLCPs as potential therapeutic agents to combat chronic
inflammatory diseases. Further investigations should explore the potential use
of SLCP in the prevention and/or therapy of inflammation-linked diseases but
future in vivo studies on SLCP are warranted to determine the clinical efficacy
of these formulations of curcumin.
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1.6. Figure legends
Fig. 1: Effects of SLCP formulations on: a) Nitrite and b) PGE2 production
in LPS-stimulated RAW 264.7 cells. Cells were co-treated with LPS (50
ng/mL) and samples (10, 25, 50 µg/mL) for 24 h. SLCP-1 and SLCP-2
inhibited NO and PGE2 levels in LPS-stimulated macrophages in a
concentration-dependent manner. Data are expressed as mean values ± SD.
a

P < 0.001 and bP < 0.01 indicate a significant difference as compared with the

LPS-treated group.

Fig. 2: Effect of SLCP formulations on LPS-induced production of proinflammatory cytokines including IL-6 in RAW 264.7 cells. The SLCP
formulations were able to suppress IL-6 levels in a concentration dependent
manner. Data are expressed as mean values ± SD. aP < 0.001 and cP < 0.05
indicate a significant difference as compared with the LPS-treated group.

Fig. 3: Effect of SLCP formulations on NF-κB activation in stimulated
RAW 264.7 macrophages. The SLCP formulations significantly inhibited the
transcriptional activity of NF-κB in LPS-activated murine macrophages at
tested concentrations. Data are expressed as mean values ± SD. aP < 0.001
indicate a significant difference as compared with the LPS-treated group.
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1.7. Tables
Table 1. Solubility of curcumin extract and the SLCP formulations in
water.
Solubility in water

Solubility in water

Fold

(%)

(µg/mL)

improvement

Curcumin (unformulated)

0.00006

0.6

1

SLCP-1 (Longvida®)

14

140,000

233,000

SLCP-2 (Longvida®)

76

760,000

1,270,000

Test samples
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1.8. Figures

Fig. 1: Effects of SLCP formulations on: a) Nitrite and b) PGE2
production in LPS-stimulated RAW 264.7 cells.
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Fig. 2: Effect of SLCP formulations on LPS-induced production
of pro-inflammatory cytokines including IL-6 in RAW 264.7 cells.
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Fig. 3: Effect of SLCP formulations on NF-κB activation in
stimulated RAW 264.7 macrophages.
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Supplementary Fig.1

Effects of SLCP preparations on the cell viability of LPS
stimulated RAW 264.7 macrophages.
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2.1. Abstract
The in vitro anti-inflammatory effects of a phenolic-enriched Canadian maple
syrup ethyl acetate extract (MS-EtOAc) and 15 purified phenolic constituents
were evaluated in a LPS-stimulated RAW 264.7 murine macrophage cell
model. MS-EtOAc decreased nitric oxide (NO) and prostaglandin-E2 (PGE2)
production at 10-100 µg/mL concentrations. The observed NO inhibition was a
direct result of reduced nitric oxide synthase (iNOS) protein and gene
expression through suppression of NF-κB transcriptional activation. In
addition, MS-EtOAc upregulated cyclooxygenase-2 (COX-2) mRNA and
protein expression. Among the 15 pure isolates, (E)-3,3'-dimethoxy-4,4'dihydroxystilbene was most effective in decreasing both NO and PGE2 levels.
However, 4-acetylcatechol, tyrosol, and protocatechuic acid only reduced
PGE2 levels. Thus, the potential anti-inflammatory activity of MS-EtOAc can be
attributed to its unique combination of compounds and not as a result of a
single purified phenolic constituent alone. Future research on the purified
phenolic compounds will be useful in understanding the overall in vitro antiinflammatory effects of maple syrup.

Keywords: Maple syrup extract; Phenolics; Inflammation; RAW 264.7
Macrophages; Lipopolysaccharide
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Abbreviations
Nuclear factor kappa B (NF-κB); nitric oxide (NO); prostaglandin-E2 (PGE2);
prostaglandins (PGs); tumor necrosis factor-α (TNF-α); interleukin-1 (IL-1);
interleukin-6 (IL-6); cyclooxygenases (COX); nitric oxide synthase (NOS);
cyclo-oxygensase-2 (COX-2); inducible nitric oxide synthase (iNOS); Maple
syrup ethyl acetate extract (MS-EtOAc); lipopolysaccharide (LPS); fetal bovine
serum (FBS); Dulbecco’s modified Eagle’s medium (DMEM); Quantitative realtime polymerase chain reaction (qRT-PCR); enzyme-immunoassay (EIA);
phosphate buffered saline (PBS); tris-buffered saline with Tween 20 (TBST);
relative light units (RLU)

42

2.2. Introduction
Functional foods and nutraceuticals, consumed for human health promotion
and disease risk reduction, are among the fastest growing sectors of the
modern food industry (Hardy, 2000). This has led to increased interest into the
discovery and applications of new functional ingredients, from both marine and
terrestrial sources, by several research laboratories (Marete, Jacquier, &
O’Riordan, 2011; Vo & Kim, 2013). Similarly, our group has been involved in
the identification of bioactive compounds from maple (Acer) species and
maple syrup (Li & Seeram, 2010, 2011a, 2011b; González-Sarrías, Li, &
Seeram, 2011; Apostolidis, Li, Lee, & Seeram, 2011). Notably, our research
efforts in this area have contributed, in part, to the recent commercial
development and utilization of maple sap/water as a functional beverage
(Yuan, Li, Zhang & Seeram, 2013; http://ilovemaple.ca/products/maple-water).
In the current project, we have now focused our attention on investigating the
biological activities of a ‘phenolic-enriched and sugar-reduced’ extract derived
from maple syrup (further explained below) for future potential applications as
a functional food ingredient.
Maple syrup is a natural sweetener produced by concentrating the
watery sap collected from maple species including the sugar maple (Acer
saccharum) and red maple (Acer rubrum) species, which are both native to
North America (Li & Seeram, 2010; Perkins & van den Berg, 2009). Maple
syrup contains sugars (mainly as sucrose), organic acids, amino acids,
minerals, and phytochemicals, the latter of which occur primarily as phenolics
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(Abou-Zaid, Nozzolillo, Tonon, Coppens, & Lombardo, 2008; Ball, 2007; Li &
Seeram, 2010). As mentioned above, our laboratory has previously isolated
and identified more than fifty phenolics from maple syrup belonging to the
lignan, coumarin, stilbene, and phenolic derivative sub-classes (Li & Seeram,
2010, 2011a, 2011b).
Published studies have shown that phenolic-enriched extracts of maple
sap and syrup have in vitro anti-oxidant, anti-proliferative, anti-radical and antimutagenic activities (Legault, Girard-Lalancette, Grenon, Dussault, & Pichette,
2010; Theriault, Caillet, Kermasha, & Lacroix, 2006). In addition, our group
has shown that phenolic-enriched maple syrup extracts and their purified
constituents inhibit the growth of human colon cancer cell lines mediated by
cell cycle arrest (González-Sarrías, Li, & Seeram, 2011). We also reported
that maple syrup extract inhibits the activities of α-glucosidase and α-amylase
enzymes using in vitro models (Apostolidis, Li, Lee, & Seeram, 2011).
However, until now, the anti-inflammatory activity and the associated
molecular mechanisms elicited by phenolic-enriched maple syrup extract have
not been thoroughly studied.

Furthermore, the activities of the purified

phenolic compounds isolated from maple syrup that may be responsible for
any observable anti-inflammatory activities have not been reported.
Inflammation is implicated in multiple chronic human diseases, such as
cancer,

diabetes,

cardiovascular

and

neurodegenerative

diseases.

Overwhelming data suggests that the nuclear factor kappa B (NF-κB)
signaling pathway is a predominant upstream molecular signaling pathway
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that causes inflammation through enhanced cytokine, nitric oxide (NO), and
prostaglandin (PG) production (Guo, Kong, & Meydani, 2009; He & Karin,
2011; Santangelo, et al., 2007; Vallabhapurapu & Karin, 2009). NF-κB, a
homo- or hetero-dimeric inducible transcription factor, resides in the cytoplasm
in an inactive state and when activated, translocates to the nucleus (Valovka &
Hottiger, 2011). In the nucleus, the activated form of NF-κB induces the
transcription of genes encoding pro-inflammatory mediators such as
prostaglandin-E2 (PGE2), NO, and other inflammatory mediators such as
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) in
response to pathologic stimuli (Park, Lee, Lee, & Kim, 2013). NO and PGE2
are widely used as anti-inflammatory activity markers for high throughput
biologically active compound screening (Djoko, Chiou, Shee, & Liu, 2007).
Both NO and PGs are synthesized by inducible isoforms of the enzymes, nitric
oxide synthase (NOS) and cyclooxygenases (COX), respectively (Chiu & Lin,
2008; Korhonen, Lahti, Kankaanranta, & Moilanen, 2005; Posadas, et al.,
2000). Cyclooxygensase-2 (COX-2) and inducible nitric oxide synthase (iNOS)
have critical roles in the response of tissues to injury or infectious agents.
These inducible enzymes are essential components of the inflammatory
response, injury repair, and carcinogenesis (Posadas, et al., 2000; Vane &
Botting, 1998). The activated form of NF-κB has been found to mediate
cancer, atherosclerosis, myocardial infarction, diabetes, arthritis, Alzheimer’s
disease, osteoporosis, and other inflammatory diseases (Kaltschmidt &
Kaltschmidt, 2009; Morgan & Liu, 2011). Thus, dietary agents that can
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suppress NF-κB activation, such as plant natural products, including
phenolics, can potentially prevent, delay the onset, or treat NF-κB mediated
diseases (Lau, Joseph, McDonald, & Kalt, 2009; Mortensen, et al., 2008; Park,
et al., 2012; Saracino & Lampe, 2007). Currently, many well-known dietary
plant phenolics, such as resveratrol, curcumin, and quercetin, are thought to
elicit anti-inflammatory and health promoting effects through downregulation of
the NF-κB signaling pathway in macrophages (Kang, et al., 1999; Kang, Heng,
Yuan, Baolin, & Fang, 2010; Korhonen, et al., 2005; Rasheed, et al., 2009).
Moreover, previous research has shown that plant extracts and their purified
compounds inhibit the pro-inflammatory COX-2 enzyme and the transcription
factor, NF-κB (Henry, et al., 2009; Rettig, et al., 2008).
In the present study, we examined the potential for a phenolic-enriched
maple syrup ethyl acetate extract (MS-EtOAc) to reduce inflammation
endpoints

in

lipopolysaccharide

(LPS)-stimulated

RAW

264.7

murine

macrophages in vitro. The inflammatory markers, NO and PGE2, along with
NF-κB activity, were measured. Lastly, 15 individual phenolic compounds
(structures shown in Fig. 1 and identities shown in Table 1), previously
isolated from maple syrup by our group (Li & Seeram, 2010, 2011b), were
evaluated for their effects on NO and PGE2 production in the LPS-stimulated
macrophages.
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2.3. Materials and Methods
2.3.1. Phenolic-enriched maple syrup ethyl acetate extract (MS-EtOAc)
Maple syrup was donated to our laboratory by the Federation of Maple Maple
Syrup Producers of Quebec and was extracted with ethyl acetate as
previously reported (González-Sarrías, Li, & Seeram, 2011). The extract was
standardized to phenolic content by the Folin–Ciocalteau method as 34%
gallic acid equivalents as previously reported (González-Sarrías, Li, &
Seeram, 2011).

2.3.2. Isolation and identification of pure compounds from maple syrup
The isolation and identification of compounds from maple syrup have been
previously reported (Li & Seeram, 2010, 2011b). The maple syrup isolates are
predominantly phenolics belonging to lignan, coumarin, stilbene, and phenolic
derivative sub-classes. Unfortunately, since many of the compounds were
isolated in small quantities, and we were limited by sample availability, we
were only able to pursue studies on 15 of the pure compounds (identities are
shown in Table 1; chemical structures are shown in Fig. 1). In addition,
because of limited quantity of these pure samples, we were only able to
evaluate each sample once (in a 96-well format) but at three different
concentrations for the bioassays described below.
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2.3.3. Cell culture and treatment
RAW 264.7 mouse macrophage cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% v/v fetal bovine
serum (FBS), penicillin G (100 U/mL), and streptomycin (100 µg/mL) (SigmaAldrich, St. Louis, MO) and maintained at 37 ºC in 5% CO2 humidified air.
RAW 264.7 cells were seeded (1 x 105 cells/100 µL) in 96-well plates. After 24
h incubation, RAW 264.7 cells were stimulated with 50 ng/mL LPS (SigmaAldrich, St. Louis, MO), followed by treatment with varying concentrations of
MS-EtOAc extract (10, 50 and 100 µg/mL) or pure compounds (10, 25, 50
µM) for 24 h. MS-EtOAc extract and the pure compounds were solubilized in
DMSO by sonication. The final DMSO concentration in the culture medium
was < 0.3%. Negative controls were not treated with LPS, MS-EtOAc extract
or pure compounds. Resveratrol (50 µg/mL) (Sigma-Aldrich, St. Louis, MO)
was used as a positive control for the assays, as it has been previously
described to decrease LPS-induced NO and PGE2 induction in RAW 264.7
cells through NF-κB downregulation (Djoko, et al., 2007; Tsai, Lin-Shiau, &
Lin, 1999). After 24 h incubation, cell culture supernatants were collected for
NO and PGE2 measurements. Cell lysates were collected for both gene
expression and protein expression analyses. For gene expression studies,
RAW 264.7 cells were seeded in a 24-well plate at 1 × 106 cells/500 µL
density. For Western blot analysis, cells were plated in a 6-well plate at 2 ×
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106 cells/mL density. Cell supernatants and lysates were stored at -80°C until
use.

2.3.4. Cytotoxicity Assay
The viability of RAW 264.7 macrophages after 24 h of continuous exposure to
MS-EtOAc extract (10-100 µg/mL) or the pure compounds (10 - 100 µg/mL), in
the presence or absence of LPS (50 ng/mL), was determined. The MTS [3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2Htetrazolium salt] assay (Promega, Madison, CA) was performed as described
previously (Li, Henry, & Seeram, 2009) with modifications. Briefly, after 24 h of
treatment, 20 µL of the MTS reagent in combination with the electron-coupling
agent, phenazine methosulfate, were added to each reaction well. The cells
were incubated at 37°C in a humidified incubator for 2 h and the absorbance
was measured at 490 nm using a spectrophotometer (SpectraMax M2,
Molecular Devices Corp, Sunnyvale, CA).

2.3.5. Nitric oxide (NO) activity
The nitrite levels in the cell culture supernatants were assayed as an indicator
of NO production, according to the Griess reaction as previously described by
Legault, Girard-Lalancette et al. (2010). Briefly, cell culture supernatants were
incubated (1:1) with modified Griess reagent (Sigma-Aldrich, St. Louis, MO)
for 20 min at room temperature. The optical densities were measured at 540
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nm and NO concentration was determined by comparison to a standard curve.
The assay was performed in triplicate and repeated at least 4 times.

2.3.6. Prostaglandin E2 release
The Prostaglandin E2 Metabolite (PGE2) assay is based on the conversion of
all major PGE2 metabolites into a single stable derivative, which is measured
by using an enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor,
MI). Briefly, the protocol was followed using the manufacturer’s protocol:
(https://www.caymanchem.com/app/template/Product.vm/catalog/514010)
whereby cell culture supernatants were used to examine the effects of the test
compounds on PGE2. The experiment was performed with three individual
samples per treatment.

2.3.7. RNA isolation and qRT-PCR
For gene expression studies, RNA was extracted from RAW 264.7 cells after
24 h treatment with MS-EtOAc. Briefly, the medium was removed and the
cells were washed with phosphate buffered saline (PBS). Total RNA was
isolated with TRIzol (Invitrogen, CA, USA) according to the manufacturer’s
instructions. The RNA concentration was determined by measuring UV
absorbance of the sample at 260 nm using a NanoDrop (Wilmington, DE,
USA). RNA samples were stored at -80 °C until use. Total RNA (1 µg) was
reverse transcribed to cDNA using the Transcriptor Reverse Transcriptase
cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN). According to
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the

manufacturer’s

website

(http://www.roche-applied-

science.com/shop/products/transcriptor-high-fidelity-cdna-synthesis-kit), the kit
contains a Transcriptor High Fidelity Reverse Transcriptase which is a blend of
a recombinant reverse transcriptase and a proofreading mediating enzyme as
a key component. Gene expression was measured in qRT-PCR reactions
using

SYBR-green

with

gene-specific

oligonucleotide

Technologies, Grand Island, NY) using LightCycler® 480

primers

(Life

(Roche Applied

Science, Indianapolis, IN). Relative mRNA expression of each gene was
normalized to the β-actin housekeeping gene. The experiment was performed
in triplicate.

2.3.8. Western blotting
To extract protein for Western blot analyses, cells were harvested and washed
with PBS. The whole cell protein extracts were prepared using RIPA buffer.
The protein lysates were separated by 10% SDS-PAGE. The proteins were
transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA) prior
to blocking for 1 h in Blotto (Santa Cruz biotechnology, Santa Cruz, CA) and
then incubated with primary antibodies specific to iNOS, COX-2, or β-actin
(Santa Cruz biotechnology, Santa Cruz, CA) for 2 h. Membranes were washed
3 times with tris-buffered saline with 0.1% Tween 20 (TBST) and then
incubated with respective anti-rabbit or anti-mouse secondary antibodies
conjugated to horseradish peroxidase (Sigma-Aldrich, St. Louis, MO) for 45
min. Bands were visualized on X-ray films using ECL chemiluminescence
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detection kit (GE Healthcare, Piscataway, NJ) according to the manufacturer’s
manual.

2.3.9. Transient transfection and luciferase assay
LPS-induced NF-κB upregulation accounts for a part of LPS-mediated
activation of variety of other inflammatory genes. Hence it is important to
identify the effects of MS-EtOAc extract on the transcriptional activity of NF-κB
(Djoko, et al., 2007). To monitor these effects of the MS-EtOAc extract, RAW
264.7 macrophages were transiently co-transfected with pNF-κB and pRLCMV reporter vectors (Promega, Madison, CA) using GenePORTER® 3000
Transfection Reagent (Genlantis, San Diego, CA) according to the
manufacturer’s protocol. Briefly, the cells were seeded into 96-well plates (1.2
× 104 cells/100 µL) in complete medium without antibiotics (DMEM +10%FBS)
and incubated for 24 h (~50-70% confluency). Cells were then treated with the
transfection complexes and incubated for 72 h before treatment with MSEtOAc extract (10, 50 and 100 µg/mL) for 2 h. LPS was added after 2 h (1
µg/mL) for 24h. After 5 h, cells were lysed with 20 µL 1x passive lysis buffer
and NF-κB activity was measured as relative firefly/renilla luciferase activity
using a Dual-Luciferase® Reporter Assay System (Promega, Madison, CA)
with a GloMaxTM 20/20 Luminometer (Promega, Madison, CA) according to
the manufacturer’s protocol. All samples were tested in quadruplicate.
Luciferase activity was recorded as relative light units (RLU) and expressed as
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fold change relative to LPS-treatment control and the assay was performed
using three biological replicates.

2.3.10. Statistical analysis
All statistical analyses were carried out using the software program GraphPad
Prism Version 5.0 (GraphPad Software, La Jolla, CA). Experimental data were
grouped by one variable and were analyzed by unpaired two-tailed t-test or
one-way ANOVA followed by a Dunnett's multiple comparison test. A value of
p < 0.05 was considered significant.

2.4. Results and Discussion
2.4.1. MS-EtOAc extract inhibit NO production in LPS-stimulated RAW 264.7
cells
In order to study the anti-inflammatory activity of maple syrup phenolicenriched extract, a well-known inflammatory marker, namely NO, was
selected. The effects of MS-EtOAc extract on NO production was determined
by the measurement of nitrite released into the culture supernatants by LPS
stimulated RAW 264.7 cells using the Griess reagent (Guevara, et al., 1998;
Legault, et al., 2010). Nitrite levels in unstimulated RAW 264.7 cells were at
baseline levels (2.8 ± 0.2 µM). However, upon stimulation with LPS, nitrite
accumulation in the culture supernatant increased ~22-fold to 60.83 ± 2.2 µM.
Resveratrol, a known inhibitor of NO activity (Djoko, et al., 2007; Wadsworth &
Koop, 1999), was used as a positive control for comparing the activity of MS-
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EtOAc.

Resveratrol (10 µg/mL) inhibited NO release by 88.67% in LPS-

stimulated RAW 264.7 macrophages. Similar activity was obtained with MSEtOAc (Fig. 2a), which significantly reduced nitrite production by 84.9% (at 50
µg/mL) and 94.3% (at 100 µg/mL) as compared to the nitrite production by
stimulated macrophages. Thus our results show that MS-EtOAc inhibited
nitrite production in a concentration-dependent manner in LPS-stimulated
cells. These findings are in agreement with the previous study where NO
inhibition in LPS-induced RAW 264.7 macrophages was significantly higher
with a maple syrup ethyl acetate extract in comparison to that of maple sap
with a mean of about 75% NO inhibition per 25 µg/mL of extract, which
corresponds to a portion of 0.18 mL of pure maple syrup (Legault, et al.,
2010).

2.4.2. MS-EtOAc inhibits PGE2 production in LPS-stimulated RAW 264.7 cells
PGE2 also functions as a mediator of inflammation, which is produced by
metabolism of arachidonic acid by COX enzymes at inflammatory sites
(Posadas, et al., 2000). The inhibitory effects of MS-EtOAc extract on PGE2
levels in LPS-stimulated macrophages were evaluated. As shown in Fig. 2b,
PGE2 production increased following LPS treatment (14 ± 1.4 ng/mL),
whereas in the absence of LPS, PGE2 levels were close to baseline or were
undetectable. PGE2 levels were reduced to 0.8 ng/mL by resveratrol treatment.
Treatment with 100 µg/mL of MS-EtOAc extract markedly reduced PGE2
levels 85.2% in LPS-stimulated RAW 264.7 cells, to 2.1 ng/mL. However,
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lower concentrations of MS-EtOAc extract only reduced PGE2 levels by
approximately 6% as compared to LPS-induced macrophages.
Taken together, these results suggest that MS-EtOAc extract is capable
of reducing NO and PGE2 LPS-induced inflammatory effects in stimulated
RAW 264.7 macrophages. None of the tested concentrations of extract
inhibited the growth of RAW 264.7 macrophages (Supplementary Fig. 1).
Hence, the observed reduction in NO and PGE2 production by the MS-EtOAc
treatment was not attributed to cytotoxic effects.

2.4.3. Pure maple syrup isolates inhibit NO and PGE2 production in LPSstimulated RAW 264.7 cells
Because MS-EtOAc is a complex mixture of compounds that could
account for its NO and PGE2 inhibitory effects, we tested 15 of its pure isolates
for their ability to reduce NO and PGE2 production. These compounds were
previously isolated from maple syrup and their structures were elucidated by
NMR methods (Li & Seeram, 2010, 2011b).

In the MS-EtOAc phenolic-

enriched extract, compound 1 is the only stilbene, whereas compound 5 is the
only coumarin among the tested samples. Compounds 9, 10, 12, 14 and 15
were all lignans. All of the other compounds were phenolic derivatives and are
briefly categorized as follows: compound 13 contained a C6 unit; compound 11
contained a C6-C1 unit; compounds 2, 3 and 7 contained a C6-C2 unit and
compounds 4, 6 and 8 contained a C6-C3 unit. At the test concentrations, the

55

pure compounds did not exhibit any cytotoxicity in the RAW 264.7 cells (data
not shown).
Among all of the pure isolates, the only stilbene, (E)-3,3’-dimethoxy4,4’-dihydroxystilbene (compound 1), was the most active compound and
significantly inhibited NO as well as PGE2 production in a concentration
dependent manner (Table 1). At 50 µM, compound 1 decreased the nitrite
level by 92.5% and PGE2 level by 89.5% in media. These results were similar
to the effects of the well-known stilbene, resveratrol (50 µM; used as a positive
control), on the above inflammatory markers (data not shown).
As shown in Table 1, apart from compound 1, the majority of the other
pure compounds were not effective in modulating NO production in LPSstimulated macrophages. However, compounds 3, 7, and 11 reduced PGE2
levels in a concentration-dependent manner. At 50 µM concentrations,
compounds 3, 7 and 11 were the most effective in lowering PGE2 levels with
95, 72.6, and 55.3% decrease, respectively. Interestingly, in this assay, the
two most active isolates, compounds 3 and 7, both contained a C6-C2
structural motif. However, compound 2, which also contained the same C6-C2
structural motif, did not show any activity against the inflammatory markers.
Based on structure activity related observations, the active compound 3
contained two aromatic hydroxyl groups while the inactive compound 2
contained three aromatic hydroxyls. Moreover, the active compound 7 only
contained one aromatic hydroxyl group. Therefore, it would appear that ≤ two
aromatic hydroxyls are required for inhibition of PGE2 levels but further studies
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on a larger number of structurally diverse compounds would be required to
confirm this. Interestingly, compound 7, protocatechuic acid, has been shown
to have anti-oxidant, anti-inflammatory and anti-cancer activity in vitro and in
vivo (Lende, et al., 2011; Nakamura, et al., 2000; Reis, et al., 2010; Robbins,
2003).
Our data with compound 11, tyrosol, a well-known constituent of olive
oil, was in agreement with a previous study where the reported IC50 value for
tyrosol for lowering NO level was >100 µM (Choe, et al., 2012). Tyrosol (at 1,
2 and 4 mM concentrations) has been shown to inhibit iNOS and COX-2
expression in RAW 264.7 cells stimulated with IFN-γ and gliadin through
reduction in NF-κB, interferon regulatory factor-1 (IRF-1) and signal transducer
and activator of transcription-1α (STAT-1α) activity (De Stefano, et al., 2007).
However, this is the first report to show that tyrosol (at 50 µM test
concentration) inhibits PGE2 level in RAW 264.7 cells stimulated by LPS.
Based on the above observations (detailed in Sec. 3.1 - 3.3), our
findings suggest that the unique combination of phenolic phytochemicals in
MS-EtOAc extract may be responsible for its anti-inflammatory activity. It is
possible that these compounds work complementarily, additively, and/or
synergistically in toto to abate inflammatory processes. Unfortunately, several
of the previously reported pure compounds from MS-EtOAc were not isolated
in sufficient quantities to facilitate further biological assaying (Li & Seeram,
2010, 2011b). Thus, future studies to evaluate the effects of all of the purified
phenolic compounds from MS-EtOAc are warranted.
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During transformation of maple sap into syrup, unique phenolic and
non-phenolic compounds are formed due to the intensive heating process. For
example, Quebecol, a novel process derived phenolic compound has been
reported in maple syrup (Li & Seeram, 2011a). It has been demonstrated that
transformation of maple sap in syrup improves NO inhibition activity. The
heating process involved in the transformation of maple sap in syrup induces
oxidation of the phenolics, suggesting its implication in the activity (Legault, et
al., 2010). Further research is needed to identify these compounds as they
may contribute to the observed biological effects of maple syrup.

2.4.4. Effect of MS-EtOAc extract on iNOS and COX-2 mRNA and protein
expression in LPS- stimulated RAW 264.7 murine macrophages
In macrophages exposed to LPS, iNOS and COX-2 mRNA and protein
expression are modulated, which ultimately results in overproduction of NO
and PGE2. In order to assess whether the inhibitory effects of MS-EtOAc
extract on NO and PGE2 were related to the alteration of iNOS and COX-2
enzymes, we examined their relative gene and protein expression by qRTPCR and western blot analysis, respectively. iNOS and COX-2 mRNA and
proteins were barely detectable in un-stimulated cells but were strongly
expressed in lysates of LPS-stimulated RAW 264.7 cells. Resveratrol
significantly decreased iNOS mRNA and protein levels at 10 µg/mL, which is
in agreement with the previous reports wherein gene activation of iNOS was
inhibited by resveratrol (Tsai, et al., 1999). MS-EtOAc decreased iNOS mRNA
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expression in a concentration-dependent manner, by 51% and 72%, at 50 and
100 µg/mL, concentrations, respectively (Fig. 3a). Not surprisingly, MS-EtOAc
extract also inhibited iNOS protein expression in a concentration-dependent
manner (Fig. 3b). These results suggest that MS-EtOAc extract likely
decreases nitrite accumulation through decreased iNOS gene and protein
expression.
The acquired data clearly indicates that MS-EtOAc extract did not
inhibit COX-2 mRNA (Fig. 4a) and protein levels (Fig. 4b) but inhibited PGE2
production as discussed previously. Since COX-2 gene expression was
upregulated by MS-EtOAc extract treatment, the inhibitory effects observed in
regards to decreased PGE2 levels may potentially occur at the translational or
post-translational levels. The reduced PGE2 levels could be due to the
inhibition at the enzymatic level by MS-EtOAc treatment. Resveratrol has also
been shown to have a direct inhibitory effect on PG production by suppressing
COX-1 and COX-2 enzyme activity in a concentration-dependent manner
(Jang, et al., 1997; Subbaramaiah, et al., 1998).
MS-EtOAc demonstrated a similar mechanism of action common to
non-steroidal anti-inflammatory drugs (NSAIDs) in inhibiting PGE2 production.
In the previous studies, NSAIDs were reported to upregulate COX-2
expression in rodents (Davies, Sharkey, Asfaha, Macnaughton, & Wallace,
1997; Minghetti, Polazzi, Nicolini, Creminon, & Levi, 1997; Pang & Hoult,
1996). Indomethacin was reported to increase COX-2 protein expression at a
concentration where it also inhibited NO synthesis and iNOS protein
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expression in LPS-induced murine macrophages (Pang & Hoult, 1996).
Similarly, ajoene, a natural product present in garlic, was also reported to
increase COX-2 gene and protein expression but it inhibited NO, PGE2 release
and iNOS expression (Dirsch, Kiemer, Wagner, & Vollmar, 1998; Dirsch &
Vollmar, 2001). In murine macrophages prostaglandins are suggested to act
as negative feedback regulators of COX-2 expression (Davies, et al., 1997;
Minghetti, et al., 1997; Pang & Hoult, 1996). Hence, inhibition of prostaglandin
production may cause upregulation of COX-2 expression as shown in our
study.
There is a complex ‘cross-talk’ between the iNOS and COX-2 pathways
as has been evidenced by numerous studies. There are reports suggesting
that NO seems to decrease COX-2 expression, however, not all published
reports are consistent. Inhibitors of nitric oxide synthase activity such as NGmonomethyl-L-arginine (L-NMMA) have been demonstrated to increase COX2 protein expression with decrease in NO production in rodent macrophages
(Habib, et al., 1997; Patel, Attur, Dave, Abramson, & Amin, 1999; Swierkosz,
Mitchell, Warner, Botting, & Vane, 1995). Reduced NO levels may contribute
to the observed increased COX-2 protein and mRNA expression with MSEtOAc treatment. Besides this negative regulation of COX-2 expression, other
potential modes of action could be an effect of MS-EtOAc on COX-2 mRNA
stability or effects at the transcriptional level. Therefore, further investigation is
required to explore how MS-EtOAc affects the COX pathway and whether it
inhibits COX activity at the enzymatic level.
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2.4.5. MS-EtOAc extract decreases NF-κB response element-luciferase
reporter construct activity
Inflammation is associated with high levels of pro-inflammatory
mediators like NO and PGE2, which are produced by the inducible isoforms of
enzymes iNOS and COX-2, respectively (Chung, et al., 2008; Nathan, 1992).
The transcription factor NF-κB, which regulates the expression of iNOS and
PGE-2, plays a crucial role in inflammatory and immune responses (Chen,
Castranova, Shi, & Demers, 1999). Thus, modulating NF-κB activating signals
is one of the widely used strategies for the treatment of diseases associated
with inflammation. Hence in order to measure NF-κB transcriptional activity,
the RAW 264.7 cells were transiently transfected with pNF-κB-luc and pRLCMV-renilla and reporter constructs were used to determine the effects of MSEtOAc extract on cells challenged with LPS. As expected, LPS treatment
increased activity of the NF-κB promoter construct by about 20-fold as
compared to control (Fig. 5). The NF-κB activity was decreased by
approximately 50% with 10 and 50 µg/mL concentrations of MS-EtOAc.
Moreover, 100 µg/mL of MS-EtOAc decreased NF-κB reporter construct
activity by ~ 75% (Fig. 5). The data herein supports the hypothesis that MSEtOAc extract may interfere with NF-κB transcriptional activity. LPS-induced
iNOS gene activation has been linked to LPS-mediated NF-κB activation
(Lowenstein, et al., 1993). Thus downregulation of iNOS expression by MSEtOAc may be through reduced NF-κB transcriptional activity.
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NF-κB is also involved in transcriptional control of IL-1-induced COX-2
gene expression (Newton, Kuitert, Bergmann, Adcock, & Barnes, 1997).
However, inflammation involves multiple complex pathways and these
pathways interfere with each other. Thus, NF-κB is not the only transcription
factor in LPS-mediated COX-2 gene expression in the mouse macrophages. It
has been reported previously that NF-κB site is not essential for LPS-mediated
COX-2 gene expression in RAW 264.7 macrophages (Wadleigh, Reddy,
Kopp, Ghosh, & Herschman, 2000). This might explain the elevated COX-2
gene and protein expression.
On the basis of current results, we propose that the anti-inflammatory
effect of maple syrup extract could be attributed to the inhibition of
inflammatory modulators NO and PGE2 through suppression of NF-κB
transcription.

2.5. Conclusion
The current study is the first report to investigate the mechanisms underlying
the anti-inflammatory activity of a phenolic-enriched maple syrup extract and
several of its purified constituents. We found that the maple syrup extract and
its purified compounds significantly inhibited the production of LPS-stimulated
inflammatory markers NO, PGE2 and iNOS through the direct inhibition of NFκB transcriptional activity in RAW 264.7 macrophages. However, the
upregulation of COX-2 gene and protein levels remain unexplained. Overall,
the cellular mechanisms underlying these multiple effects may be attributed to
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the unique combination of pure compounds present in the extract, which
appear to act in toto. More detailed research is needed to get further insights
into the exact anti-inflammatory mechanism of the MS-EtOAc extract.
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2.6. Figure legends
Fig. 1 Compounds isolated from an ethyl acetate extract of Canadian
maple syrup (MS-EtOAc).

Fig. 2 Effect of MS-EtOAc extract on NO (a) and PGE2 (b) production in
LPS-stimulated RAW 264.7 cells.
The cells were co-incubated with LPS (50 ng/mL) and different concentrations
of MS-EtOAc extract ranging from 10 -100 µg/mL for 24 h. The supernatants
were then collected for the measurement of NO and PGE2 production using
Griess reagent and an EIA kit, respectively. MS-EtOAc extract significantly
inhibited NO (2a) and PGE2 (2b) levels in LPS-stimulated macrophages. The
values are expressed as the means ± S.D. of three individual samples. ***P <
0.001 as compared with the LPS-treated macrophages; significant differences
between groups were determined using a one-way ANOVA test followed by a
Dunnett’s multiple comparison test. #P < 0.05 solvent control compared with
the LPS-treated cells; significant difference was determined using unpaired
student-t test.

Fig. 3 Effects of MS-EtOAc on iNOS mRNA and protein levels in LPS
treated macrophages.
RAW 264.7 cells were co-treated with LPS (50 ng/mL) and various
concentrations of MS-EtOAc extract (10, 50,100 µg/mL) for 24 h. (3a) iNOS
mRNA levels were determined as described in Section 2. iNOS mRNA
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transcript levels were normalized to β-actin expression. MS-EtOAc extract
inhibited iNOS mRNA expression in a concentration-dependent manner. Data
are expressed as the means ± S.D. of three different samples. (3b) iNOS and
housekeeping gene GAPDH expressions were monitored as described in
Section 2.8. MS-EtOAc extract inhibited iNOS protein expression in a
concentration dependent manner. ***P < 0.001 as compared with the LPStreated group; significant differences between groups were determined using a
one-way ANOVA test followed by Dunnett’s multiple comparison test. #P <
0.05 solvent control compared with the LPS-treated cells; significant difference
was determined using unpaired student-t test.

Fig. 4 Effects of MS-EtOAc on COX-2 mRNA and protein expressions in
LPS-stimulated RAW264.7 macrophages.
(4a) RAW 264.7 cells were co-treated with LPS (50 ng/mL) and various
concentrations of MS-EtOAc extract (10, 50,100 µg/mL) for 24 h. 1 µg of total
cellular RNA was subjected to RT-PCR followed by SYBR-green quantitative
real-time PCR. COX-2 mRNA transcript levels were normalized to β-actin
expression. MS-EtOAc extract increased COX-2 mRNA expression in a
concentration dependent manner. Data are expressed as the means ± S.D. of
three different samples. (4b) COX-2 protein expression was measured as
described in section 2.8. MS-EtOAc extract treatment increased COX-2
protein expression. ***P < 0.001 as compared with the LPS-treated group;
significant differences between groups were determined using a one-way
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ANOVA test followed by Dunnett’s multiple comparison test. #P < 0.05 solvent
control compared with the LPS-treated cells; significant difference was
determined using unpaired student-t test.

Fig. 5 Effects of MS-EtOAc on LPS induced NF-κB luciferase activity in
macrophages.
RAW 264.7 cells were transiently co-transfected with pNF-κB and pRL-CMV
reporter vectors. NF-κB activity was measured using a Promega dual
luciferase assay system. MS-EtOAc significantly reduced the LPS-induced
increase

in

NF-κB-dependent

luciferase

enzyme

expression

in

a

concentration-dependent manner. Data is the mean ± S.D. of three different
samples. *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with the LPStreated group; significant differences between groups were determined using a
one-way ANOVA test followed by Dunnett’s multiple comparison test. #P <
0.05 solvent control compared with the LPS-treated cells; significant difference
was determined using unpaired student-t test.

66

2.7. Tables
Table 1: Effect of pure compounds isolated from an ethyl acetate extract of
Canadian maple syrup (MS-EtOAc) on NO and PGE2 levels in LPS-induced
RAW 264.7 macrophages.*

No

% NO
inhibition
at 50 µM

Name

1

(E)-3,3'-Dimethoxy-4,4'-dihydroxystilbene

2

3',4',5'-Trihydroxyacetophenone

3

4-Acetylcatechol

% PGE2 inhibition
10
25
50
µM
µM
µM

92.5

30.2

76.5

89.5

0

0.0

0

7.5

6.5

56.0

88.6

95.0

1

0.0

0.0

0.0

0

0.0

0.0

0.0

0

0.0

0.0

0.0

Tyrosol
3-Hydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)
propan-1-one

1.6

0.0

45.0

72.6

0

0.0

0.0

0.0

Isolariciresinol
5-(3'',4''-dimethoxyphenyl)-3-hydroxy-3-(4'hydroxy-3'-methoxybenzyl)-4- (hydroxymethyl)
dihydrofuran-2-one
Protocatechuic acid (3,4-Dihydroxybenzoic
acid)
Threo-guaiacylglycerol-β-O-4'-dihydroconiferyl
alcohol
4-Hydroxycatechol (hydroxyhydroquinone)

1.7

0.0

0.0

0.0

0

0.0

2.0

6.2

0

13.8

31.5

55.3

0

0.0

0.0

0.0

0

0.0

0.0

0.0

14 Sakuraresinol

6.4

0.0

5.8

28.1

15 Syringaresinol

2.2

0.0

7.5

23.8

4
5
6
7
8
9
10
11
12
13

2,3-Dihydroxy-1-(3,4-dihydroxyphenyl)-1propanone
Isofraxidin
2,3-Dihydroxy-1-(4-hydroxy-3,5dimethoxyphenyl)-1-propanone

*The cells were incubated with 50 ng/mL LPS and 10, 25 and 50 µM of pure compounds (1-15). After 24 h, the
supernatants were collected for determination of NO by Griess reaction and PGE levels by EIA assay. Data is the
2

mean ± S.D. of three different samples.
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2.8. Figures

Fig. 1 Compounds isolated from an ethyl acetate extract of
Canadian maple syrup (MS-EtOAc).
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Fig. 2 Effect of MS-EtOAc extract on NO (a) and PGE2 (b)
production in LPS-stimulated RAW 264.7 cells.
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Fig. 3 Effects of MS-EtOAc on iNOS mRNA and
protein levels in LPS treated macrophages.
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Fig. 4 Effects of MS-EtOAc on COX-2 mRNA and protein
expressions
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Fig. 5 Effects of MS-EtOAc on LPS induced NF-κB luciferase
activity in macrophages.
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Supplementary Fig. 1
Effect of MS-EtOAc extract on cell viability in LPS-induced RAW 264.7
cells. The cells were co-incubated with LPS (50 ng/mL) and different
concentrations of MS-EtOAc extract ranging from 10-100 µg/mL for 24 h. The
MTS-PMS reagent (20 µL) was then added and the optical densities were
measured after 2 h. The values are expressed as the means ± S.D. of three
individual samples.
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3.1. Abstract	
  
Pure maple syrup is highly regarded as a natural sweetener. Our laboratory
has conducted extensive chemical and biological studies characterizing maple
syrup and we have developed a food grade standardized maple syrup extract
(named, MSX), which is well tolerated in rats. In this project, firstly we explored
mechanism involved in hypoglycemic effects of MSX in HepG2 cells. Glucose
lowering effects of MSX (at 100 µg/mL) was attributed to increased AMPK
phosphorylation and lowered gluconeogenic gene expression as compared to
control. Secondly, we also evaluated the anti-lipogenic effect of MSX
treatment in mature differentiated 3T3-L1 murine adipocytes and human
visceral adipocytes. MSX treatment (at 50, 100 µg/mL concentrations) to
mature adipocytes decreased lipid accumulation compared to control in both
murine and human adipocytes. In 3T3-L1 adipocytes, this effect was
associated with downregulation of adipo/lipogenic protein expression (e.g.
PPARγ, SREBP-1). We also observed reduced mRNA expression of the proinflammatory mediators, namely IL-6, and TNF-α. The current study adds to
the growing body of in vitro and in vivo data supporting the biological effects
and potential health benefits of the natural sweetener, maple syrup. 	
  
	
  
	
  
	
  
Keywords: Maple syrup; Phenolics; 3T3L1; HepG2; AMPK; gluconeogenesis;
lipogenesis	
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Tris buffered saline/Tween-20 (TBST); Phosphoenolpyruvate carboxykinase
(PEPCK); Glucose-6-phosphatase (G6pase); Acetyl-CoA carboxylase-1 (ACC1); Glucose transporter (GLUT4), Fatty-acid-binding protein (FABP4);
Lipoprotein lipase (LPL); Fatty acid synthase (FAS); Tumor necrosis factor-α
(TNF-α); Interleukin-6 (IL-6) 	
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3.2. Introduction :	
  
In last few decades, the prevalence of type 2 diabetes mellitus (T2DM) has
radically increased. Insulin resistance (IR) along with hyperglycemia and
hyperinsulinaemia is the hallmark of T2DM. In T2DM, hyperglycaemia is
predominantly caused by atypical increase in hepatic gluconeogenesis,
leading to drastic increase in glucose levels (1, 2). Metformin, a well-known
anti-diabetic drug, primarily corrects hyperglycaemia and hyperinsulinaemia by
lowering hepatic gluconeogenesis via 5’ adenosine monophosphate-activated
kinase (AMPK) activation (3). 	
  
There is also an established link between obesity and diabetes due to related
inflammatory processes (4). Obesity leads to increased circulation of proinflammatory markers leading to ‘metabolic inflammation’ which has been
linked to the pathogenesis of IR and T2DM in humans and animal models (4).
The de-lipidating effects of a well-studied polyphenol, resveratrol, via
peroxisome proliferator-activated receptor γ (PPARγ), CCAAT-enhancerbinding protein (C/EBPα) and sterol-regulatory element-binding protein
(SREBP-1) etc., is well established (5). Phenolics have attracted significant
research attention due to their diverse biological functions and potential
positive effects on human health (6-8). Plant natural products, especially those
rich in phenolics, have been shown to exert anti-inflammatory properties and
therefore may have beneficial effects against diseases with an inflammatory
component such as diabetes, obesity, cancer, cardiovascular disease, and
arthritis(9-14).	
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Despite the availability of a wide variety of sweeteners, there is increasing
consumer demand for natural sweeteners among which pure maple syrup is
highly regarded. Maple syrup has different grades (ranging from light to amber
to dark, based on light transmittance) and is predominantly used for table
consumption. Notably, the maple syrup industry generates large volumes of
dark and ‘off-flavored’ grades of maple syrup, which are not suitable for table
consumption and are regarded as industrial ‘by-products’. Similar to other food
industries, for e.g. cranberry extracts being produced from the squeezed fruit
pulp left over after juice extraction, these maple by-products are viable starting
materials for the maple syrup industry to use to develop a food grade maple
syrup-derived botanical extract. Recently, our laboratory has conducted
extensive chemical and biological studies on a laboratory-scale phenolicenriched maple syrup extract. This work led to development of a nutraceutical
grade maple syrup-derived extract (named, MSX) starting from by-products of
the industry (15). MSX is chemically standardized and well tolerated by rats
(non-toxic at doses of up to 1000 mg/kg/day), has a reduced sugar content
compared to maple syrup (ca. 50% vs. 66%; constituting sucrose and complex
polysaccharides) and maintains the natural profile of constituents (minerals,
vitamins, organic acids, amino acids, phytohormones and phytochemicals)
found in the food. Dietary compounds ‘phenolics’ are predominantly present
among other phytochemicals in maple syrup extract. Given the beneficial
health effects of polyhenols, herein we propose that polyphenol-rich MSX with
unique chemical matrix would exert potential positive biological effects. 	
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Our recent published studies have shown that a laboratory scale phenolicenriched extract of maple syrup decreases nuclear factor kappa B (NF-κB)
activity and downstream inflammatory targets in murine macrophages (16).
Moreover, maple syrup extracts have been shown to have antioxidant (6), αglucosidase enzyme inhibitory (17), anticancer (18) and anti-inflammatory (19)
properties in vitro. In addition, maple syrup has been shown to have liver
protective effects (20), improve metabolic response (21), and ability to reduce
plasma glucose level compared to a sucrose solution alone (22, 23) in animal
models. Recently, St-Pierre et al., (2014) reported that maple syrup produced
low glycaemic and insulinaemic responses in vivo, and thus represents a
natural sweetener alternative to refined sugar (21). Recently, our lab has
reported MSX treatment lowered media glucose levels as compared to control
in human HepG2 cells (15). However, the mechanism behind hypoglycemic
effect of MSX is still unknown. Therefore, given all of above published in vitro
and animal data, we believe that further investigation into demonstrating the
hypoglycemic and hypolipidemic effects of this novel MSX extract is
warranted. 	
  
In this investigation, we hypothesized that nutraceutical grade MSX extract
lowered glucose levels via AMPK phosphorylation in hepatocytes. Moreover,
we postulate the de-lipidating effects of MSX extract by downregulating the
lipogenic targets in mature adipocytes.	
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3.3. Materials and Methods :	
  
3.3.1. Chemicals	
  
The cell lines HepG2 and 3T3-L1 preadipocytes were purchased from
American Type Culture Collection (ATCC) (Manassas, VA, USA). Human
visceral adipocytes and the reagents for maintaining and differentiating them
were purchased from Lonza biotechnology. Cell culture reagents such as
Dulbecco's modified Eagle’s medium (DMEM), Hank's balanced salt solution
(HBSS), fetal bovine serum (FBS) and fetal calf serum (FCS) were obtained
from Lonza biotechnology. Trypsin-EDTA (ethylenediaminetetraacetic acid)
and penicillin–streptomycin were bought from Gibco BRL (Gaithersburg, MD,
USA). Metformin, resveratrol, Oil Red O (ORO), isobutylmethylxanthine
(IBMX), dimethyl sulfoxide (DMSO), primary antibody anti-β-actin and
peroxidase-conjugated secondary antibodies were purchased from SigmaAldrich (St. Louis, MO, USA). All primary antibodies were obtained from Cell
Signaling Technology, Inc. (Beverly, MA, USA) except anti-SREBP1 and antiPEPCK antibodies were purchased from Abcam. ECL™ detection reagent
was bought from GE Healthcare (Buckinghamshire, UK). Glucose assay kit
was purchased from Eton Bioscience (San Diego, CA, USA). High-capacity
cDNA reverse transcription kit was from Applied Biosystems (Foster City, CA,
USA). SYBR Green PCR Master Mix was obtained from Roche Applied
Science (Indianapolis, IN, USA). Protein assay kit was purchased from BioRad. Immobilion polyvinylidene difluoride (PVDF) membranes were bought
from Millipore EMD Corporation (Billerica, MA, USA). Zhang et al. (2014) had
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previously described the preparation and chemical composition of the maple
syrup nutraceutical extract (named, MSX), which was used in this study (15). 	
  
	
  
3.3.2. HepG2 Cell culture and treatment	
  
HepG2 cells were maintained in a high-glucose (4.5 g/L) DMEM supplemented
with 10% FBS, 2 mM glutamine, 1000 U/L penicillin and 100 mg/L
streptomycin at 37 °C, 5% CO2, as described previously (15). The cells were
seeded into a 12-well plate at a density of 4 x 104 cells/well and cultured for 68 h. The cells were incubated with the low-glucose (1 mg/L) DMEM detection
media supplemented with 2 mM glutamine and 1% FBS. After overnight
incubation, the cells were treated with metformin (1 mM) or MSX extract (at 50
and 100 µg/mL; stock solutions made in DMSO) diluted in the low glucose
detection medium. The final DMSO concentration was 0.1% (v/v) in the test
extracts. The cell supernatants and the cell lysates were collected after 24 h
treatment.	
  
	
  
3.3.3. Adipocyte culture and treatment	
  
3T3-L1 preadipocytes were maintained in DMEM containing 10% FCS, 100
U/mL penicillin and 100 µg/mL streptomycin to confluence at 37°C. The cells
were seeded in 6-well and 24-well plates Adipocyte differentiation was induced
at 2 days post-confluence (Day 0), using a mixture of IBMX (0.5  mM),
dexamethasone (0.25  µM), and insulin (5  µg/mL) in DMEM containing 10% of
FBS. On day 2, day 4 and day 6, this medium was replaced with DMEM
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containing 10% of FBS and insulin only. The medium was switched to DMEM
containing 10% of FBS on day 8 for 24 h. On day 9, the cells were treated with
MSX extract (at 50 and 100 µg/mL) and after 48 h the cell culture media and
cell lysates were collected and stored at -80°C until analysis. To put the data
from our assays into context, other therapeutics know to impact adipocyte
function were included, such as metformin (4 mM) or resveratrol (50  µM/10
µg/mL) in these in vitro assays. These concentrations were chosen based
upon previous studies that have reported the effective concentrations of the
above-mentioned positive controls in the adipocytes for lowering the lipid
content (24, 25).	
  
Human visceral adipocytes were cultured and differentiated as per the
manufacturer’s instructions (Lot # 0000313366). Briefly, human primary
preadipocytes were grown to confluence in Preadipocyte growth medium-2
provided in 5% CO2 at 37°C. When the cells reached confluence, the medium
was replaced with Preadipocyte differentiation medium supplemented with a
cocktail of insulin, dexamethasone, indomethacin and isobutyl-methylxanthine
to Preadipocyte Growth Medium-2 for 10 days and cells were monitored for
lipid droplet formation. After 10 days of culture, the adipocyte medium was
withdrawn and cells were incubated with the MSX extract (100 µg/mL) and
positive controls. After 24 h, the cell culture media was removed and the cells
were stained with ORO solution for visualizing lipid droplets.	
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3.3.4. Glucose Consumption Assay 	
  
The glucose concentration in the HepG2 cell supernatants was determined
using a glucose assay kit as per the manufacturer’s instructions. Absorbance
was measured at 490 nm using a spectrophotometer (SpectraMax M2,
Molecular Devices Corp, Sunnyvale, CA, USA), and the assay was performed
in triplicates.	
  
	
  
3.3.5. Oil red O staining and quantification	
  
During differentiation of pre-adipocytes into adipocytes, intracellular lipid
droplets are accumulated. ORO dye is used for staining these lipid droplets
(26, 27). Briefly, after incubation with test extracts for given period of time the
cells were washed twice with phosphate buffered saline (PBS); followed by
fixing with 10% formalin for 1 h. The cells were washed twice with PBS and
stained with filtered ORO solution (150 mg/ 50 mL Oil Red O and 60% (v/v)
isopropanol in distilled water) for 15 min. The cells were then thoroughly
washed with distilled water before imaging under an optical microscope at x10
magnification (EVOS FL Auto, Life technologies, Carlsbad, CA, USA).
Then the Oil Red O retained in the cells was extracted with isopropanol, the
absorbance

was

spectrophotometrically

determined

at

570  nm

using

SpectraMax M2 (Molecular Devices Corp, Sunnyvale, CA, USA).

3.3.6. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
Total RNA was extracted using a Trizol reagent and 1 µg of the extracted RNA
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was reverse transcribed into cDNA using a cDNA reverse transcription kit.
Then the mRNA expression levels were quantified by quantitative real-time
PCR using SYBR Green PCR Master Mix and the Lightcycler 480 Real Time
PCR system (Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s protocol. The quantification of gene expression with real-time
PCR data was calculated relative to β-actin gene expression.
	
  
3.3.7. Western blot	
  
The cells were washed once with phosphate-buffered saline and lysed in RIPA
buffer. Protein concentration was measured using a bichonic protein assay kit.
Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto PVDF membranes. After 1
h incubation in blocking solution (5% skim milk), the membranes were
incubated overnight with primary antibodies in cold room. The membranes
were washed thrice with Tris buffered saline/Tween-20 (TBST) for 10 min
each

followed

by

incubation

with

horseradish

peroxidase-conjugated

secondary antibodies for 1 h at room temperature. The membranes were
again washed three times with TBST and then developed on X-ray films using
ECL™ detection reagent. The bands were quantified using the Image J
program (NIH, Washington, DC, USA).	
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3.3.8. Statistical analyses	
  
All statistical analyses were carried out using the software program GraphPad
Prism Version 5.0 (GraphPad Software, La Jolla, CA, USA). Results are
expressed as the means ± the standard error of the mean (S.E.). The
experimental data was analyzed by unpaired one-tailed t-test (for compairing
differences between two individual groups) or one-way ANOVA (for comparing
differences between all groups together) followed by a Dunnett's multiple
comparison test. p < 0.05 was considered significant.	
  
	
  
3.4. Results & Discussion:	
  
3.4.1. MSX increase glucose consumption in HepG2 cells by downregulating
gluconeogenic genes via AMPK activation	
  
It has been reported that natural products can regulate glucose and lipid
metabolism in HepG2 liver hepatocytes (28). Similarly, in our recent MSX
study (15) in HepG2 cells, MSX lowered glucose levels in the media along with
clinical anti-diabetic drug metformin, after brief incubation for 7 h. Given that
MSX decreased glucose levels in HepG2 cells through increased glucose
consumption, it was investigated whether MSX constituents are activators of
the AMPK pathway, which suppress gluconeogenesis (29), similar to
metformin (30). Herein, the treatment was extended further for 24 h in HepG2
cells as contrast to our recent study in which the cells were treated only for 7
h. Briefly, HepG2 cells were incubated with low glucose media overnight
followed by treatment with MSX (50 and 100 µg/mL) or metformin (100 µM or
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1 mM) for 24 h. The cell culture media was collected for measurement of
glucose. As shown in Fig. 1, MSX (100 µg/mL) reduced media glucose levels
to 70% of DMSO treated control cells. Next, the expression of gluconeogenic
rate limiting enzymes, (e.g. phosphoenolpyruvate carboxykinase [PEPCK] and
glucose-6-phosphatase [G6pase], was evaluated (31). After 24 hrs MSX (100
µg/mL) treatment, G6pase mRNA expression was reduced to 68% of control.
However, PEPCK mRNA expression was similar to vehicle-treated controls
(Fig. 2). 	
  
In order to conduct further investigation into gluconeogenic pathway, upstream
regulator AMPK protein expression was studied. AMPK activation is commonly
detected by monitoring its phosphorylation at Thr-172 and phosphorylation of
downstream target acetyl-CoA carboxylase-1 (ACC-1), using phospho-specific
antibodies. ACC-1 is a key enzyme involved in fatty acid synthesis, which is
phosphorylated and inactivated by AMPK (32). MSX (100 µg/mL) slightly
increased the ratio of pAMPK/ AMPK and pACC-1/ ACC-1 by about 40% and
26% of control, respectively (Fig. 3). 	
  
Moreover, MSX reduced the expression of PEPCK protein to about 55% and
43% of control at 50 µg/mL and 100 µg/mL concentration, respectively. Thus,
MSX could be inhibiting PEPCK at translational level (Fig. 3) but not
transcriptionally (Fig. 2). 	
  
Thus, glucose-lowering effect of MSX at higher concentration (100 µg/mL)
could be attributed to downregulation of G6pase gene expression and PEPCK
protein expression through AMPK activation. These results supported the
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published in vivo studies with maple syrup; which reported reduced plasma
glucose levels compared to a sucrose solution alone in an anti-diabetic animal
model (22, 23). However, this is a preliminary study and further more detailed
in vivo studies are needed to support this data.	
  
	
  
3.4.2. MSX imparts lipid-lowering effects in mature mouse and human
adipocytes 	
  
Next, MSX was evaluated for anti-lipogenic effects in mature mouse 3T3-L1
and human visceral adipocytes. Figs. 4A and 4C depict ORO staining of lipid
droplets in 3T3-L1 adipocytes and human visceral adipocytes treated with
DMSO vehicle (0.1%), resveratrol (50 µM), metformin (1- 4 mM), or MSX (50
and/or 100 µg/mL). Metformin and resveratrol were selected because of
documented anti-lipogenic activity in both differentiated 3T3-L1 and human
adipocytes (24, 25, 33). Resveratrol, at the concentration selected, reduced
the staining to 78% of vehicle-treated control adipocytes (Fig. 4B). In contrast,
metformin and MSX (50 and 100 µg/mL) decreased the ORO staining by
approximately 40-50% of control (Fig. 4B). To put our data in context with
human health perspective, we tested MSX in mature adipocytes from a human
donor. Metformin and MSX treatment reduced ORO staining in human
adipocytes to 64% and 43% of vehicle-treated controls, respectively (Fig. 4D).	
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3.4.3. MSX downregulated lipogenic targets in mature 3T3-L1 adipocytes. 	
  
In metabolic syndrome, adipocytes play crucial role in lipid storage and
metabolism (34). In adipocytes, several transcription factors act in concert
during the adipogenesis and lipogensis phase, including PPARγ, C/EBPα, and
SREBP-1 (34-36). In order to explore the molecular mechanisms involved in
MSX anti-lipogenic effects, the cell lysates were collected after 48 h treatment
for evaluating lipogenic target protein expression in mature 3T3-L1 adipocytes.
Fig. 5 illustrates that MSX downregulated adipo/lipogenic transcription factors
(i.e. PPARγ, C/EBPα and SREBP-1 protein expression). PPARγ and C/EBPα
regulate the expression of variety of genes that are involved in different
pathways including insulin sensitivity (glucose transporter GLUT4), lipogenesis
(fatty-acid-binding protein, FABP4) and lipolysis (lipoprotein lipase, LPL,
perilipin) and the secreted factors (adiponectin and leptin) (37). Here, we
investigated the effect of MSX treatment on two targets, FABP4 and perilipin,
in differentiated adipocytes. FABP4 is involved in fatty acid uptake, transport,
and metabolism (38), whereas perilipin is localized at the periphery of lipid
droplets and plays a pivotal role in lipid storage (39). MSX treatment
downregulated the expression of these downstream targets in a concentration
dependent manner. SREBP-1 induces the expression of lipogenic enzymes,
including ACC-1 and fatty acid synthase (FAS) (34). MSX decreased protein
expression of both ACC-1 and FAS in a concentration dependent manner.
These observations depict decreased protein expression of adipo/lipogenic
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targets after MSX treatment, which are consistent with reduced lipid staining in
MSX-treated mature adipocytes depicted in Fig 4. 	
  
It is now well accepted that inflammation and associated pro-inflammatory
processes are centrally linked to several chronic human diseases including
obesity and diabetes (40). Hence, after exhibiting anti-lipogenic effect, MSX
also demonstrated specific effects on mature adipocytes that likely contribute
to its overall anti-inflammatory effects. TNF-α and IL-6 are two key mediators
of the inflammatory response in mature 3T3-L1 adipocytes that have been
linked to obesity-related inflammation. Thus, MSX effect on adipocyte
inflammation was explored by measuring TNF-α and IL-6 mRNA expression
(Fig. 6). At 48 hours, resveratrol reduced TNF- α or IL-6 mRNA expression to
60% and 40% of control respectively. In addition, MSX treatment at 50 µg/mL
also reduced TNF-α and IL-6 to about 20% of control, however 100 µg/mL
MSX treatment reduced both inflammatory targets to 36-47%. This is in
agreement with our previous research where we have exhibited antiinflammatory effects of MSX (15) and maple syrup ethyl acetate extract (16) in
lipopolysaccharide-induced macrophages. Moreover, in this study we have
demonstrated inhibitory effect of MSX treatment on inflammatory markers in
mature adipocytes. This is not surprising as MSX contains high levels of
polyphenols, which are well-known antioxidants and anti-inflammatory agents
(41). Interestingly, MSX contains stilbenes which are structurally related to
resveratrol, a well-known polyphenol, thus we could anticipate MSX antilipogenic and anti-inflammatory effects (15). 	
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MSX also contains high quantity of phytohormone abscisic acid (ABA), which
has been proposed to improve insulin sensitivity and obesity-related
inflammatory diseases through a PPAR γ-dependent mechanism. ABA is
structurally similar to thiazolidinediones (drugs prescribed for diabetic
management) (42). Dietary abscisic acid has been reported to improve
glucose tolerance and obesity-related inflammation in db/db mice fed high-fat
diet (43). MSX is particularly rich in lignans and these polyphenolic
compounds are also found in flaxseed. Interestingly, flaxseed lignan have
been shown to inhibit fat accumulation and induce adiponectin expression in
high-fat diet-induced mouse model (44).	
  
In conclusion, as depicted in Fig. 7 the lowered glucose levels after MSX
treatment were attributed to AMPK activation in HepG2 hepatoma cell model.
However, the effect of MSX-treatment were not drastic in HepG2 cells.
Moreover, we demonstrated delipidating effects of MSX extract treatment by
downregulating protein expression of adipo/lipogenic transcription factors and
their downstream targets in differentiated 3T3L1 adipocytes (Fig. 6). In future,
it would be interesting to explore mechanistic insights into obesity-linked
inflammatory pathway using MSX-treated human adipose tissue explants.	
  
This study, using in vitro models, provided preliminary data necessary to guide
and support future in vivo studies investigating the potential use of a novel
food grade maple syrup extract (MSX) as a nutraceutical preparation for
positive impact on overall health.	
  
	
  

	
  

97

Acknowledgement	
  
This project was supported by Agriculture and Agri-Food Canada from the
Developing Innovative Agri-Products (DIAP) program. This work was also
supported by grants from the National Institute of Health [4R01ES016042,
5K22ES013782 to ALS] for the supplies. Spectrophotometric data were
acquired from instruments in the RI-INBRE core facility located at the
University of Rhode Island (Kingston, RI, USA) supported by grant #
5P20GM103430-13 from the National Institute of General Medical Sciences of
the National Institutes of Health. PN was supported by a graduate student
scholarship from the Omar Magnate Family Foundation.	
  
	
  
Conflict of interest	
  
The authors declare no conflicts of interest.	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

98

3.5. Figure legends
Fig. 1. Effect of MSX extract on glucose levels in the media in HepG2
hepatoma cells. Cells were treated with MSX (50 and 100 µg/mL) or
metformin (100 µM) in a low glucose media for 24 h and the cell supernatants
were collected. MSX extracts inhibited glucose levels in the media in a
concentration-dependent manner. The values are expressed as the means
±SE of three individual samples. ‘*’ indicates P < 0.05 as compared with the
control.

Fig. 2. Effect of MSX extract on mRNA expression of genes involved in
gluconeogenesis, namely G6pase (A) and Pepck (B) in HepG2 hepatoma
cells. Cells were treated with MSX (50 and 100 µg/mL) or metformin (1 mM) in
a low glucose media for 24 h and the cell lysates were collected. MSX extracts
downregulated the gene expression of G6pase (A) and Pepck (B). The values
are expressed as the means ±SE of three individual samples. ‘*’ indicates P <
0.05 as compared with the control.

Fig. 3. Effect of MSX extract on protein expression of pAMPK, pACC and
Pepck in HepG2 hepatoma cells. Cells were treated with MSX (50 and 100
µg/mL) or metformin (1 mM) in a low glucose media for 24 h and the cell
lysates were collected. MSX extracts upregulated the expression of pAMPK,
pACC, and Pepck.	
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Fig. 4. Effect of MSX extract on lipid accumulation by ORO staining and
quantification in mature 3T3-L1 (A,B) and human visceral adipocytes
(C,D). Cells were treated with MSX (50 and 100 µg/mL) or metformin (1 or 4
mM) or resveratrol (50 µM) for 48 h and ORO staining was performed to stain
and quantify lipid droplets in differentiated murine adipocytes (4A & 4B) and in
mature human visceral adipocytes (4C & 4D). ‘*’ indicates P < 0.05 and ‘**’
indicates P < 0.01 as compared with the control.

Fig. 5. Effect of MSX extract on protein expression of lipogenic targets
after MSX treatment in mature 3T3-L1 cells. Cells were treated with MSX
(50 and 100 µg/mL) or metformin (1 or 4 mM) or resveratrol (50 µM) for 48 h
and the cell lysates were collected after 48 h MSX treatment in mature 3T3-L1
adipocytes for protein expression. MSX extracts downregulated the protein
expression of adipo/lipogenic targets.

Fig. 6. Effect of MSX extract on gene expression of inflammatory markers
in mature 3T3-L1 adipocytes. Cells were treated with MSX (50 and 100
µg/mL) or resveratrol (50 µM) for 48 h and the cell lysates were collected for
mRNA expression. MSX extracts reduced the expression of inflammatory
genes TNF-α and IL-6 in differentiated 3T3-L1 cells. The values are expressed
as the means ±SE of three individual samples. Significant differences between
groups were determined using a one-way ANOVA test followed by Dunnett’s
multiple comparison test. ‘*’ indicates P < 0.05 as compared with the control.
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Fig. 7. MSX hypoglycemic and anti-lipogenic effect in HepG2 cells and
3T3-L1 cells.
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3.6. Figures :	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

Fig. 1. Effect of MSX extract on glucose levels in the
media in HepG2 hepatoma cells.
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Fig. 2. Effect of MSX extract on mRNA expression of
genes involved in gluconeogenesis, namely G6pase
(A) and Pepck (B) in HepG2 hepatoma cells.
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Fig. 3. Effect of MSX extract on protein expression of pAMPK, pACC
and Pepck in HepG2 hepatoma cells.	
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Fig. 4. Effect of MSX extract on lipid accumulation by ORO staining and
quantification in mature 3T3-L1 (A,B) and human visceral adipocytes
(C,D).
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Fig. 5. Effect of MSX extract on protein expression of lipogenic
targets after MSX treatment in mature 3T3-L1 cells.
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Fig. 6. Effect of MSX extract on gene expression
of inflammatory

markers in
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Fig. 7. MSX hypoglycemic and anti-lipogenic effect in HepG2 cells
and 3T3-L1 cells.
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SUMMARY AND CONCLUSION
1. In this thesis, we have demonstrated that bioactive polyphenol-rich extracts
namely- Longvida® and food grade maple syrup extract exert positive health
benefits beyond basic nutrition, thus impacting overall health and wellness.
2. A novel curcumin formulation Longvida® showed improved solubility over
unformulated curcumin, and significantly decreased the LPS-induced proinflammatory mediators in macrophages.
3. Maple syrup extract and its purified compounds significantly inhibited the
production of inflammatory markers through the direct inhibition of NF-kB
transcriptional activity in stimulated macrophages. Overall, the cellular
mechanisms underlying these multiple effects may be attributed to the unique
combination of pure compounds present in the extract, which appear to act in
toto.
4. We demonstrated delipidating effects of food-grade MSX extract treatment
by downregulating protein expression of adipo/lipogenic transcription factors
and their downstream targets in differentiated murine 3T3L1 adipocytes. MSX
treatment also decreased lipid accumulation in human adipocytes. MSX
extract could also have potential application in obesity-linked inflammation.
5. In conclusion, this study, using in vitro models, provided preliminary data
necessary to guide and support future in vivo studies investigating the
potential use of a novel curcumin formulation Longvida® and food grade
maple syrup extract (MSX) as a nutraceutical preparation for positive impact
on overall health.	
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